Clinical trials: Endometrial Cancer
Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
This is a prospective, multi-center, open-label, single-arm, non-randomized, Phase II study to evaluate the efficacy and safety of TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced and/or…
- Conditions
- Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer, Second-line Treatment, VEGF
- Trial name
- NCT01379534
- Testing
- TKI258
- Where
- 45 sites in United States, Brazil and 5 more
- Volunteers
- 53 people
- Sponsor
- Novartis Pharmaceuticals
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma
Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens plus radiation therapy in treating patients who have stage III or stage IV endometrial cancer.
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
- Trial name
- NCT00006011
- Testing
- Doxorubicin Hydrochloride, Cisplatin, Filgrastim
- Where
- United States
- Volunteers
- 659 people
- Sponsor
- Gynecologic Oncology Group
Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma
Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer
This phase II trial studies how well temsirolimus works in treating patients with endometrial cancer that has spread to other parts of the body or has spread from where it started to nearby tissue or lymph nodes and has come back…
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma
- Trial name
- NCT00072176
- Testing
- temsirolimus, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Pelvic Neoplasms
Treatment of Hemorrhagic Radiation Proctitis Using the Halo System
This study involves evaluating a procedure in which the study device, the HALO90 Ablation catheter, is used to heat a thin layer of tissue lining the rectum using radiofrequency (RF) energy in subjects suffering from radiation…
- Trial name
- NCT01103492
- Testing
- HALO90 Ablation catheter
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Endometrial Cancer
Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer
Primary Objective: To estimate the antitumor activity of the combination of gemcitabine and cisplatin in patients with advanced (stage III or IV) or recurrent endometrial cancer.
- Trial name
- NCT00388154
- Testing
- Gemcitabine, Cisplatin
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Cancer
Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00470067
- Testing
- carboplatin, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
Endometrial Cancer
Papillary Serous Carcinoma of the Endometrium
Primary Objectives: To evaluate the results of Paclitaxel and pelvic radiation in pelvic confined papillary serous carcinoma of the endometrium for both local control and overall survival.
- Trial name
- NCT00515073
- Testing
- Paclitaxel, Pelvic Radiation, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Sleep, Endometrial Neoplasms
Sleep and Endometrial Cancer
This study proposes to test the hypothesis that zolpidem taken the night before major surgery for endometrial cancer will improve sleep efficiency and reduce post surgery pain, as well as reduce the need for analgesic medication.
- Conditions
- Sleep, Endometrial Neoplasms, Pain
- Trial name
- NCT00936598
- Testing
- zolpidem, sugar pill
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- University of Pittsburgh
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Fallopian Tube Cancer, Ovarian Sarcoma
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
RATIONALE: Stereotactic radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This clinical trial studies stereotactic radiosurgery using CyberKnife works in treating women with…
- Conditions
- Fallopian Tube Cancer, Ovarian Sarcoma, Ovarian Stromal Cancer, Recurrent Cervical Cancer
- Trial name
- NCT01079832
- Testing
- stereotactic radiosurgery, quality-of-life assessment
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Case Comprehensive Cancer Center
Endometrial Cancer
Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer
The goal of this clinical research study is to learn if cetuximab can help to control the disease in patients who have recurrent endometrial cancer. Primary Objective: 1.
- Trial name
- NCT00392769
- Testing
- Cetuximab
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Cancer
Feasibility Study Using the Xoft System for the Treatment of Endometrial Cancer
Multicenter, non-randomized, feasibility study to evaluate the treatment and assess acute safety of the FDA Cleared Axxent Electronic Brachytherapy System and vaginal applicator for intracavitary vaginal cuff treatment according…
- Trial name
- NCT01045187
- Testing
- brachytherapy, Xoft Axxent Electronic Brachytherapy System
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Xoft, Inc.
Endometrial Carcinoma
Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.
The purpose of this study is to determine the efficacy of a monthly administration of Fulvestrant in patients with recurrent or metastatic endometrial carcinoma by assessment of the clinical tumour response after 3 injections.
- Trial name
- NCT00334295
- Testing
- Fulvestrant
- Where
- 9 sites in Germany
- Volunteers
- 35 people
- Sponsor
- AstraZeneca
Neoplasms, Endometrial, Endometrial Cancer
Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer
The purpose of this study is to find out if Hycamtin given weekly is safe and effective for treating your endometrial cancer.
- Trial name
- NCT00267488
- Testing
- topotecan
- Where
- 24 sites in United States, Canada and 1 more
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer
RATIONALE: Pyridoxine (vitamin B6) may prevent or lessen hand-foot syndrome caused by chemotherapy. It is not yet known whether pyridoxine is more effective than a placebo in preventing hand-foot syndrome.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Endometrial Cancer, Fallopian Tube Cancer
- Trial name
- NCT00245050
- Testing
- pyridoxine hydrochloride, doxorubicin HCL liposome
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Neoplasms, Neoplasms by Site
A Trial for Patients With Advanced/Recurrent Endometrial Cancer
The intent of this protocol is to screen a new agent for activity in patients with advanced or recurrent endometrial carcinoma. This phase II trial is studying how well pemetrexed disodium works in treating patients with advanced…
- Conditions
- Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Genital Neoplasms, Female
- Trial name
- NCT00377520
- Testing
- pemetrexed
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Eli Lilly and Company